このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Pharvaris マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Berndt Axel Modig

最高経営責任者

€532.0k

報酬総額

CEO給与比率	100.0%
CEO在任期間	9yrs
CEOの所有権	2.8%
経営陣の平均在職期間	2.6yrs
取締役会の平均在任期間	3.7yrs

経営陣の近況

Recent updates

CEO報酬分析

Pharvaris の収益と比較して、Berndt Axel Modig の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€114m
Mar 31 2024	n/a	n/a	-€106m
Dec 31 2023	€532k	€532k	-€101m
Sep 30 2023	n/a	n/a	-€107m
Jun 30 2023	n/a	n/a	-€92m
Mar 31 2023	n/a	n/a	-€83m
Dec 31 2022	€500k	€500k	-€76m
Sep 30 2022	n/a	n/a	-€49m
Jun 30 2022	n/a	n/a	-€50m
Mar 31 2022	n/a	n/a	-€53m
Dec 31 2021	€414k	€414k	-€43m
Sep 30 2021	n/a	n/a	-€41m
Jun 30 2021	n/a	n/a	-€38m
Mar 31 2021	n/a	n/a	-€29m
Dec 31 2020	€404k	€404k	-€26m

報酬と市場: Berndt Axelの総報酬 ($USD 571.24K ) は、 US市場 ($USD 3.40M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Berndt Axelの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Berndt Axel Modig (65 yo)

9yrs

在職期間

€532,000

報酬

Mr. Berndt Axel Edvard Modig, MBA, CPA, serves as Chief Executive Officer since 2015 and Executive Director of Pharvaris B.V. Mr. Modig served as a Member of the Supervisory Board at Centogene N.V. since A...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Berndt Axel Modig	Co-Founder	9yrs	€532.00k	2.79% € 28.2m
Anna Nijdam	Head of Strategic Finance & Principal Accounting Officer	no data	データなし	0.093% € 942.6k
Stefan Abele	Chief Technology Operations Officer	less than a year	データなし	データなし
Annick Deschoolmeester	Chief Human Resources Officer	2yrs	データなし	0.033% € 334.9k
Peng Lu	Chief Medical Officer	4.6yrs	データなし	0.84% € 8.5m
Anne Lesage	Chief Early Development Officer	no data	データなし	0.93% € 9.4m
Morgan Conn	Chief Business Officer	no data	データなし	0.50% € 5.1m
Wim Souverijns	Chief Commercial Officer	3.2yrs	データなし	0.20% € 2.0m
David Nassif	CFO & Corporate Secretary	less than a year	データなし	データなし
Maryann Cimino	Director of Corporate Relations	no data	データなし	データなし

2.6yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: PHVSの経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Berndt Axel Modig	Co-Founder	no data	€532.00k	2.79% € 28.2m
Robert Glassman	Independent Non-Executive Director	3.7yrs	€50.50k	0.062% € 626.0k
David Meeker	Independent Non-Executive Chair	3.7yrs	€94.00k	0.23% € 2.3m
Hans J. G. C. Schikan	Independent Vice Chairman	5.1yrs	€61.00k	0.94% € 9.5m
Elisabeth Bjork	Non-Executive Director	2.8yrs	€45.00k	0.041% € 414.7k
Viviane Monges	Non-Executive Director	3.2yrs	€62.50k	0.059% € 595.4k

3.7yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: PHVSの取締役会は経験豊富であると考えられます ( 3.4年の平均在任期間)。

Pharvaris マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Recent updates

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Pharvaris Expands Development Program for Deucrictibant

Co-Founder notifies of intention to sell stock

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Early Development Officer notifies of intention to sell stock

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Independent Vice Chairman notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris: Digging Deep For Sufficient Market Size

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023

New major risk - Shareholder dilution

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Co-Founder notifies of intention to sell stock

Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer

New major risk - Revenue and earnings growth

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Announces Board Changes

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris N.V., Annual General Meeting, Jun 23, 2023

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Less than half of directors are independent

Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V., Annual General Meeting, Jun 29, 2022

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris N.V. Appoints Joan Schmidt as Chief Legal Officer

Less than half of directors are independent

High number of new and inexperienced directors

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris reports Q1 results

Independent Non-Executive Director has left the company

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE

Pharvaris B.V. has completed an IPO in the amount of $165.41 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

マネジメント基準チェック /34